INS and metabolic dysfunction-associated steatotic liver disease: GE ameliorates NAFLD in mice and rats, directly targeting COX-1 activity as well as its downstream TXA2 biosynthesis, while the TXA2 pathway might mediate NAFLD progression by impairing insulin sensitivity [159].